A Study to Evaluate D-2570 in Participants With Moderate to Severe Plaque Psoriasis (NCT07489885)
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase II Study to Evaluate the Efficacy and Safety of D-2570 in Participants With Moderate to Severe Plaque Psoriasis
🩺 Plain-English Summary (8th-Grade Level)
A Study looking at the safety and efficacy of D-2570 in Participants with Plaque Psoriasis
Who can join: To join this study, participants generally need to meet the listed inclusion criteria (3 items) and avoid the listed exclusions (2 items).
Location: Study Center — Birmingham, Alabama
Age range: 18 Years to 70 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistCheck every box below. If you can check all of them, you may meet the study's basic screening requirements (final eligibility is confirmed by the site team).
Usually NOT eligible if any of the following apply:
- Exclusion Criteria:
- Any comorbidities or past medical conditions as outlined in the protocol that would interfere with study assessments as deemed by the Investigator
🔍 Extracted verbatim from the official NIH eligibility criteria. Always confirm with the study coordinator.
📍 All Participating Trial Locations (20 Sites)
- Study Center — Birmingham, Alabama
- Study Center — Phoenix, Arizona
- Study Center — Chula Vista, California
- Study Center — Fountain Valley, California
- Study Center — Fremont, California
- Study Center — Los Angeles, California
- Study Center — Los Angeles, California
- Study Center — San Diego, California
- Study Center — Fort Lauderdale, Florida
- Study Center — Miramar, Florida
- Study Center — Ocala, Florida
- Study Center — Tampa, Florida
- Study Center — Sandy Springs, Georgia
- Study Center — Savannah, Georgia
- Study Center — Idaho Falls, Idaho
- Study Center — Clarksville, Indiana
- Study Center — Louisville, Kentucky
- Study Center — Mayfield Heights, Ohio
- Study Center — Philadelphia, Pennsylvania
- Study Center — San Antonio, Texas
📞 Contact the Study Coordinator
Phone: (302) 519-5966
Email: kathryn.stazzone@inventisbio.com
Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Psoriasis
- A Real-world Observational Study to Compare Effectiveness of Deucravacitinib Vs Apremilast in Adults With Plaque Psoriasis — Waltham, Massachusetts
- Taltz in Combination With Enstilar for Psoriasis — East Windsor, New Jersey
- Stelara and Tremfya Pregnancy Exposure Registry OTIS Autoimmune Diseases in Pregnancy Project — La Jolla, California
- An Open-Label, Pilot Study to Evaluate the Efficacy of Narrowband Ultraviolet-B Phototherapy Three Times Weekly for Twelve Weeks in Moderate-to-Severe Psoriasis Patients — East Windsor, New Jersey
- Use of Total-Body PET to Quantify Systemic and Cutaneous Inflammation in Psoriasis Patients Before and After Intervention With a Nutritionally Balanced Diet — Sacramento, California
- Deucravacitinib Adherence Study — Winston-Salem, North Carolina
Explore by condition: All Psoriasis clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Contact the study coordinator using the phone/email above.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.